Top

BY Devon Carter

Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell lung cancer, small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, Hodgkin’s lymphoma and Merkel cell carcinoma. And the list continues to grow. 

“Immunotherapy is a modern pillar of cancer therapy,” says Vivek Subbiah, M.D., assistant professor of Investigational...

T cell immunotherapy side effects

BY Ron Gilmore

MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...

BY Clayton R. Boldt, Ph.D.

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) encompass a spectrum of diseases characterized by an overproduction of immature blood cells, resulting in a lack of healthy, mature blood cells in patients.

Unfortunately, the majority of patients with these diseases are not cured with currently available therapies, so MD Anderson’s MDS and AML Moon Shot™ team has committed to developing new treatment options...

Simona Colla, Ph.D., associate professor of Leukemia at MD Anderson

BY Clayton R. Boldt, Ph.D.

September is Ovarian Cancer Awareness Month, an annual time to bring attention to the impact of the disease. This year, more than 22,000 women...

BY Scott Merville

Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune system...

BY Ron Gilmore

Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with...

BY Julie Penne

MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...

BY Clayton R. Boldt, Ph.D.

A well-trained research workforce is essential for addressing both current and future health challenges in the U.S. However, according to...

BY Clayton Boldt, Ph.D.

MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched Magnolia...

BY Scott Merville

MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer, opening new...

BY Clayton R. Boldt, Ph.D.

Many are aware of the importance of cancer research for the discovery of new therapies and treatment options, but perhaps less well-known...

BY Scott Merville

A study led by MD Anderson found the investigational drug quizartinib prolongs overall survival for patients with a deadly form of acute myeloid...

BY Scott Merville

When Elizabeth White started a new job as executive director of the Michigan Ovarian Cancer Alliance in 2017, she decided it...

BY Ron Gilmore

A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits...

BY Clayton R. Boldt, Ph.D.

Excluding skin cancers, prostate cancer is the most commonly diagnosed cancer among men in the United States. According to the American Cancer...

BY Michael Hardy

Most people think of hypnosis as a kind of party trick — a mischievous way to make somebody unconsciously do your bidding.

But...

BY Clayton R. Boldt, Ph.D.

Immunotherapy, which stimulates the patient’s own immune system to attack cancer, has shown promise in treating a variety of cancer types...

BY Lany Kimmons

For their role in transforming cancer care, three MD Anderson faculty received the American Society of Clinical Oncology’s Special Awards...

BY Laura Sussman

Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared...

BY Laura Sussman

In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held...

BY Laura Sussman

In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...

BY Clayton R. Boldt, Ph.D.

Understanding evolution within cancer cells is a longtime interest for Nicholas Navin, Ph.D., an associate professor of Genetics and Bioinformatics...

BY Laura Sussman

In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved...

BY Sarah Watson

Eight MD Anderson researchers have been selected as the newest class of Andrew Sabin Family Fellows. As part of the Andrew Sabin Family Fellowship...

BY Michael Hardy

Shortly after arriving at MD Anderson in 1987 as a junior faculty member, Guillermina Lozano, Ph.D., attended several seminars hosted by the...

BY Payal Pandit Talati, MPH

Reducing the incidence of melanoma through primary and secondary prevention is among one of the shared goals and key partnership strategies...

BY Clayton R. Boldt, Ph.D.

Each May, Skin Cancer Awareness Month serves as a reminder of how individuals can work to lower their risk of skin cancer – the most common...

BY Bryan Tutt

Patients with recurrent or second primary head and neck cancer who previously received radiation therapy to the head and neck region – especially...

BY Ron Gilmore

Triple-negative breast cancer (TNBC) is an aggressive form of the disease that doesn’t rely on the hormones estrogen and progesterone or the...

BY Clayton Boldt, Ph.D.

By July 31, all U.S. Department of Housing and Urban Development (HUD) housing will be required to be smokefree, in accordance to rule put...

BY Scott Merville

Immunotherapy has taken hold as an effective treatment for a variety of advanced cancers, but so far, colorectal cancer has...

BY Scott Merville

Immune cells that rush to repair damage caused by inflammatory tissue are subverted to cancer-promoting allies by pancreas cells that feature...

BY Clayton R. Boldt, Ph.D.

Fewer than 30% of the women in the U.S. with abnormal, benign lesions known as atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS...

BY Clayton R. Boldt, Ph.D.

Despite the availability of vaccines that could prevent the majority of cancers caused by the human papillomavirus (HPV), the incidence of...

BY MD Anderson staff

“Driving Innovative Cancer Science to Patient Care” was the theme of the American Association for Cancer Research’s annual meeting, which...

BY Ron Gilmore

The American Association for Cancer Research (AACR) has selected Isaiah J. Fidler, D.V.M., Ph.D., professor of Cancer Biology, as recipient...

BY Scott Merville

Melanoma cells are able to evade cancer immunotherapy by using a specific protein to hide from immune system T cells out to seek and destroy...

BY Ronda Wendler

When people breathe, there’s movement inside their bodies.

Organs, tissues and even cancer patients’ tumors move around all the time...

BY Ron Gilmore

MD Anderson was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30% of the $73.5...

BY Clayton Boldt, Ph.D.

MD Anderson’s Colorectal Cancer Moon Shot™ is committed to the prevention and early detection of the third most common cancer diagnosed in...

BY Ron Gilmore

Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes...

BY Bryan Tutt

Radiation therapy to the whole breast or chest wall and the internal mammary lymph nodes can deliver a radiation dose to the heart that increases...

BY Scott Merville

Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal...

BY Scott Merville

A cold virus engineered to attack the most common and deadly of brain tumors allowed 20% of patients with recurrent glioblastoma to live for...

BY Scott Merville

Organizations in Spain and Saudi Arabia recognized the leadership of Jim Allison, Ph.D., MD Anderson chair of Immunology, in cultivating the...

BY Scott Merville

A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared...

BY Ron Gilmore

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone disease that accounts for one-fourth of all breast cancers, could...

BY Lany Kimmons

In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from MD Anderson Cancer...

BY Clayton Boldt, Ph.D.

Increasing the dosage of a prescription smoking cessation medication by 1 milligram a day – from 2 to 3 milligrams – more than doubled abstinence...

BY Joe Munch

Chemotherapy is a proven and effective method for treating many types of cancer, but up to 90% of patients who receive the treatment develop...

BY Clayton Boldt, Ph.D.

Older patients with non-metastatic breast cancer who have been treated modern chemotherapy drugs have a greater risk of secondary acute myeloid...

BY Sarah Bronson

Until recently, patients with esophageal cancer were treated with esophagectomy, or removal of the affected part of the esophagus and surrounding...

BY Ron Gilmore

A new genetic-based model developed by an MD Anderson research team may explain how a common form of early-stage breast cancer known as ductal...